South Korea Emerges as Major Drug Licensing Hub with $7.68 Billion in Deals Driven by Eli Lilly and GSK
Key Insights
South Korea's drug licensing deal value reached $7.68 billion in 2025, representing a 113% increase from 2024, with out-licensing to international firms surging 180%.
Major pharmaceutical companies Eli Lilly and GSK fueled this growth through billion-dollar agreements, including Eli Lilly's $1.3 billion deal for RNA-based gene therapies and GSK's $2.8 billion licensing of a blood-brain barrier (search) platform.
The country established the National Bio Committee in January 2025 with plans to create a $695.7 million fund and become one of five global bio industry leaders by 2035.
South Korea has emerged as a major destination for pharmaceutical licensing deals, with transaction values reaching $7.68 billion in 2025, marking a dramatic 113% increase from the previous year. The surge positions the country alongside China as a rapidly growing hub for innovative drug development partnerships.
The momentum has been largely driven by billion-dollar agreements from major pharmaceutical companies. Eli Lilly made two significant investments: a $630 million deal for OliX Pharmaceuticals (search)' metabolic-associated steatohepatitis (search) (MASH) candidate in February, followed by a separate $1.3 billion agreement for biotech Rznomics (search)' RNA-based gene therapies in May. GSK contributed to the trend with its $2.8 billion licensing deal for ABL Bios (search)' blood-brain barrier (search) shuttle platform in April.
Strategic Transformation in Drug Development
According to GlobalData senior business fundamentals analyst Ophelia Chan, "Once primarily recognised for generic drug production, South Korea is now transitioning into a global hub for novel innovative drug discovery and advanced drug technologies, bolstered by government support and increasing international investment. This transition positions the country as a strategic bridge between Western and Asian markets."
The out-licensing of South Korean drugs to international firms has experienced particularly robust growth, surging by 180% with approximately a $5.1 billion increase from 2024 to 2025.
Government Initiative and Investment
In January 2025, South Korea established the National Bio Committee with an ambitious mandate to make the country one of five global leaders in the bio industry by 2035. The committee aims to enhance South Korea's competitiveness in novel drug and advanced biopharmaceutical technology development.
According to South Korea's Ministry of Science and IT, the committee plans to create a Won1 trillion ($695.7 million) fund to promote private investment in the biopharmaceutical and vaccine industry. The initiative builds on ongoing reforms as the government aims to reduce drug development timelines and costs.
Regional Competition and Global Context
South Korea's rise mirrors China's growth as a licensing destination, where the total deal value of US licensing of innovator drug candidates from Chinese biopharma companies has surged 280% since 2020. A bipartisan report in the US has called for at least $15 billion of funding over the next five years to avoid being eclipsed by China in biotech advancement.
Regulatory and Trade Considerations
The future relationship between US and European pharma industries with Chinese and South Korean companies faces potential challenges from trade tensions. The Trump administration has imposed tariffs while looking to bolster domestic manufacturing in the US, and has maintained that transferring technology to China poses a threat to national security.
The controversial BIOSECURE Act, which would have blacklisted Chinese biotechs and manufacturers from accessing US funding and collaborating with US pharma companies, remains in regulatory limbo. Additionally, the US Food and Drug Administration announced an immediate review of new clinical trials that involve sending American citizens' living cells to China and other countries for genetic engineering and subsequent infusion back into US patients, potentially impacting deals with Chinese contract development and manufacturing organizations.